All AbMole products are for research use only, cannot be used for human consumption.
Bemarituzumab (FPA144) is a first-in-class, humanized, afucosylated immunoglobulin G1 monoclonal antibody (mAb) directed against fibroblast growth factor receptor 2b (FGFR2b) with two mechanisms of action against FGFR2b-overexpressing tumors: inhibition of FGFR2b signaling and enhanced antibody-dependent cell-mediated cytotoxicity (ADCC).
| CAS Number | 1952272-74-0 |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[1] Peter Sidaway. Nat Rev Clin Oncol. Bemarituzumab enters the FIGHT
| Related FGFR Products |
|---|
| SNIPER(TACC3)-11
SNIPER(TACC3)-11 is a potent FGFR3-TACC3 degrader. |
| LY-3076226
LY-3076226 is an antibody drug coupling (ADC) with a cleavable linker targeting FGFR2. |
| Aprutumab ixadotin
Aprutumab ixadotin is an antibody drug coupling (ADC) with a non-cleavable linker that targets FGFR2. |
| Gunagratinib
Gunagratinib is an orally active, potent, selective, and irreversible fibroblast growth factor receptor (pan-FGFR) inhibitor for use in cancer research. |
| SAR-442501
SAR-442501 is a novel anti-FGFR3 monoclonal antibody for studies related to achondroplasia (ACH). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
